Pharming Group N.V. (PHAR)

From the record

Pharming Group N.V.'s filings since 2020 show no warning events in the scan: no bankruptcy or receivership notice, no debt default notice, no exchange listing notice, no restatement warning, no auditor change, no material cyber incident and no late-report notice (its current reports).

From the record

Pharming Group N.V.'s 7 filed years say what it did: revenue went from $189 million in fiscal 2019 to $376 million in fiscal 2025, up 12.1% a year; it rose in 5 of 6 years; the deepest fall was 6% from fiscal 2020 to fiscal 2021; net income was positive in 5 of 7 of those years (its annual reports).

From the record

Over the 3 fiscal years to 2025-12-31, Pharming Group N.V.'s diluted share count grew about 1.8% a year, and dividends and buybacks returned about 0% of its operating cash flow over 3 years (its filed statements). Its officers and directors filed 0 sales and 0 purchases of their own stock on the open market in the year to 2026-09-30 (their Form 4 filings).

From the record

Return on equity: in the fiscal year ended 2025-12-31, Pharming Group N.V. earned about 1 cents of profit for every dollar of shareholders' money, and gross profitability: its products earned about 66 cents per dollar of everything the company owns. Leverage: it owed about 45 cents per dollar of assets, and net share issuance: its share count shrank 4.9% over the year (the filed statements).

From the record

Pharming Group N.V.'s standing among 315 graded names in its industry family: revenue of $376 million in fiscal 2025 ranks in the top 21% by size; a net margin of 0.7% ranks in the top 24%; revenue growth of 22.3% a year over the last 3 filed years ranks in the top 36% (its annual reports).

From the record

Pharming Group N.V.'s room to grow, from the newest filed statements (fiscal 2025): cash of $145 million against no long-term debt tagged leaves 29.1% of its assets as net cash, top 48% of its family; cash from operations less capital spending is 14.3% of revenue (top 18%); a gross margin of 87.9% (top 21%); research spending of 26.7% of revenue (bottom 32%) (its annual report).

From the record

Pharming Group N.V.'s growth drivers, from the filed years to fiscal 2025: revenue grew 22.3% a year over the last three filed years against 12.1% over all 7, speeding up (top 18% of its family); the newest year grew 26.6% (top 33%); research spending grew 24.1% a year (top 19%); capital spending grew -18.3% a year (bottom 46%) (its annual reports). Pharming Group N.V. tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.

From the record

Pharming Group N.V.'s newest year against its own record: revenue of $376 million in fiscal 2025 came in 5.3% above the $357 million its prior three years' pace pointed to (top 37% of its family); net income of $3 million against a prior three-year average of $3 million (top 8%); a net margin of 0.7% against -0.5% before (bottom 36%) (its annual reports).